… , nirmatrelvir plus ritonavir received authorization in the EU for use in the same indication.
Nirmatrelvir plus ritonavir is … in the development of nirmatrelvir plus ritonavir leading to its first …

… ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir
plus ritonavir reduced the risk of … -to-moderate COVID-19 at high risk for progression to severe …

… The analysis included all eligible recipients of molnupiravir and nirmatrelvir/ritonavir who …
or nirmatrelvir/ritonavir reduced the risk of hospitalization and death in this highly vulnerable …

… A clinical access policy continues to support the treatment of higher-risk patients with … , and
nirmatrelvir-ritonavir in preventing hospital admission and death in higher-risk patients (Fig. 1) …

… We found that patients treated with nirmatrelvir/ritonavir had a higher probability of having
a negative test within 10 days from the first positive one. This data may be affected by some …

… COVID-19 and eligible for nirmatrelvir-ritonavir treatment, a systematic review …
nirmatrelvir-ritonavir. The objective of this study was to evaluate the performance of …

… reduce viral shedding time (VST) in high-risk SARS-CoV-2 patients, … Nirmatrelvir/Ritonavir
in order to control VST in high-risk … on Nirmatrelvir/Ritonavir, the latter percentage increased to …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

… coadministration of nirmatrelvir and ritonavir among vaccinated populations is uncertain.
This study emulated a clinical trial to assess whether nirmatrelvir plus ritonavir reduces risk for …

… After adjusting for demographics, high-risk cohort categories, … in outcome risk between
nirmatrelvir/ritonavir and sotrovimab … the risks of severe outcomes between nirmatrelvir/ritonavir …